What went wrong with the glucose-lowering arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Trials? Intensive therapy was expected to reduce cardiovascular events in Type 2 diabetics at high risk of cardiovascular disease. Instead, it appears to have led to an increase in mortality. Dr. John Buse, president of the American Diabetes Association and vice chair of the ACCORD Trials Steering Committee, details the confounding results of ACCORD and offers a few ideas to explain the unexpected outcomes. Dr. Matthew Sorrentino hosts.
Special Report: What Went Wrong With ACCORD?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
What went wrong with the glucose-lowering arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Trials? Intensive therapy was expected to reduce cardiovascular events in Type 2 diabetics at high risk of cardiovascular disease. Instead, it appears to have led to an increase in mortality. Dr. John Buse, president of the American Diabetes Association and vice chair of the ACCORD Trials Steering Committee, details the confounding results of ACCORD and offers a few ideas to explain the unexpected outcomes. Dr. Matthew Sorrentino hosts.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?